NICE recommends Roche's Ocrevus for relapse-remitting multiple sclerosis

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat relapse-remitting multiple sclerosis.

In January, the European Commission approved the second-generation humanized mAb against CD20 to treat the relapsing and primary progressive forms of multiple sclerosis (PPMS) (see "Roche's Ocrevus receives EU approval for MS")...